245 reports of this reaction
2.4% of all IRBESARTAN AND HYDROCHLOROTHIAZIDE reports
#5 most reported adverse reaction
DYSPNOEA is the #5 most commonly reported adverse reaction for IRBESARTAN AND HYDROCHLOROTHIAZIDE, manufactured by Sanofi-Aventis U.S. LLC. There are 245 FDA adverse event reports linking IRBESARTAN AND HYDROCHLOROTHIAZIDE to DYSPNOEA. This represents approximately 2.4% of all 10,188 adverse event reports for this drug.
Patients taking IRBESARTAN AND HYDROCHLOROTHIAZIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for IRBESARTAN AND HYDROCHLOROTHIAZIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for IRBESARTAN AND HYDROCHLOROTHIAZIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 245 FDA reports for IRBESARTAN AND HYDROCHLOROTHIAZIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.4% of all adverse event reports for IRBESARTAN AND HYDROCHLOROTHIAZIDE, making it a notable side effect.
If you experience dyspnoea while taking IRBESARTAN AND HYDROCHLOROTHIAZIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.